Fed. Circ. Won't Rehear Merck Temodar Patent Case
The Federal Circuit on Monday denied a bid for en banc rehearing of its November decision that a Merck & Co. Inc. patent for brain tumor treatment Temodar could be enforceable....To view the full article, register now.
Already a subscriber? Click here to view full article